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Abstract 
Background: Every year approximately 30,000 women die from hypertensive disease in pregnancy. Magnesium 
sulphate and anti-hypertensives reduce morbidity, but delivery is the only cure. Low dose oral misoprostol, a prosta-
glandin E1 analogue, is a highly effective method for labour induction. Usually, once active labour has commenced, 
the misoprostol is replaced with an intravenous oxytocin infusion if ongoing stimulation is required. However, some 
studies have shown that oral misoprostol can be continued into active labour, a simpler and potentially more accept-
able protocol for women. To date, these two protocols have never been directly compared.
Methods: This pragmatic, open-label, randomised trial will compare a misoprostol alone labour induction protocol 
with the standard misoprostol plus oxytocin protocol in three Indian hospitals. The study will recruit 520 pregnant 
women being induced for hypertensive disease in pregnancy and requiring augmentation after membrane rupture. 
Participants will be randomised to receive either further oral misoprostol 25mcg every 2 h, or titrated intravenous 
oxytocin. The primary outcome will be caesarean birth. Secondary outcomes will assess the efficacy of the induction 
process, maternal and fetal/neonatal complications and patient acceptability. This protocol (version 1.04) adheres to 
the SPIRIT checklist. A cost-effectiveness analysis, situational analysis and formal qualitative assessment of women’s 
experience are also planned.
Discussion: Avoiding oxytocin and continuing low dose misoprostol into active labour may have a number of ben-
efits for both women and the health care system. Misoprostol is heat stable, oral medication and thus easy to store, 
transport and administer; qualities particularly desirable in low resource settings. An oral medication protocol requires 
less equipment (e.g. electronic infusion pumps) and may free up health care providers to assist with other aspects of 
the woman’s care. The simplicity of the protocol may also help to reduce human errors associated with the delivery 
of intravenous infusions. Finally, women may prefer to be mobile during labour and not restricted by an intravenous 
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Background
Hypertensive disease in pregnancy is a major cause of 
the 300,000 maternal deaths that occur every year [1]. In 
South Asia alone, hypertensive disease in pregnancy is 
responsible for 10,000 deaths annually [2]. Much of this 
burden could be prevented by timely and effective deliv-
ery—the only curative intervention in pre-eclampsia.
Misoprostol, a prostaglandin E1 analogue, given in 
low doses orally is a highly effective method for labour 
induction in low resource settings. Oral administration 
of 25  µg every 2  h received a strong recommendation 
by WHO in 2011 [3]. The Cochrane review of oral mis-
oprostol found that in low doses oral misoprostol is at 
least as effective as the commonly used vaginal dinopros-
tone gel [4]. Misoprostol is also heat stable and less than 
1% of the cost of dinoprostone gel. The Cochrane review 
concluded that “low-dose oral misoprostol probably has 
many benefits over other methods for labour induction.” 
and that “a starting dose of 25 μg may offer a good bal-
ance of efficacy and safety.” A recent network meta-anal-
ysis of all prostaglandins for labour induction supported 
these conclusions, finding that oral misoprostol solution 
(< 50mcg) was the safest in terms of risk of caesarean sec-
tion [5].
Until recently, misoprostol was only available in 100 
and 200mcg tablets (Cytotec®) which had to be either cut 
or dissolved in water to obtain the 25mcg doses [6–8]. 
However, low cost, high quality 25mcg misoprostol tab-
lets have now become available, removing many of the 
logistical barriers to its use.
Standard practice for induction of labour is to use a 
prostaglandin (dinoprostone or misoprostol) for cervi-
cal ripening. When the amniotic membranes rupture 
and active labour has commenced (cervical dilation of 
more than 3-4 cm), the provider stops administering the 
prostaglandin and an intravenous infusion of oxytocin is 
started if uterine stimulation is still required [9]. Every 
30 min the infusion is increased to stimulate uterine con-
tractions sufficient to progress labour, but not so much as 
to cause hyperstimulation and consequent fetal hypoxia.
However, avoiding oxytocin and continuing low dose 
misoprostol into active labour may have a number of 
benefits for women and the health care system. Mis-
oprostol is heat stable and an oral medication and thus 
easy to store, transport and administer; all particularly 
desirable in low resource settings. The ease of adminis-
tration of an oral medication may help to reduce human 
errors associated with the delivery of intravenous infu-
sions and require less equipment (e.g., electronic infusion 
pumps). Moreover, the simplicity of the protocol, which 
eliminates the need to actively titrate an oxytocin infu-
sion against contractions, may free up health care provid-
ers to assist with other aspects of a woman’s care. Finally, 
women may prefer to be mobile during labour and not 
restricted by an intravenous infusion. There is a need, 
therefore, to compare the safety, efficacy and accept-
ability of the two augmentation protocols. The primary 
objective of this trial is to assess whether augmentation 
using oral misoprostol is superior clinically and economi-
cally to the standard protocol of intravenous oxytocin.
Methods
Trial design
We will undertake a multi-centre parallel, superiority, 
open-label randomised trial in three publicly funded 
hospitals in India: Government Medical College Nagpur, 
Daga Memorial Women’s Hospital and Mahatma Gandhi 
Institute of Medical Sciences.
Participants and recruitment
Research staff will invite 1,000 potentially eligible women, 
due to undergo induction of labour with oral misopros-
tol, to provide advance written informed consent in case 
they become eligible. We estimate that 1,000 women 
undergoing induction will be required in order to obtain 
a sample size of 520 for the randomised trial, as not all 
patients will require additional drugs after artificial rup-
ture of membranes. The randomised study will enrol 520 
pregnant women, ≥ 18 years of age, with a live fetus, who 
require induction because of pre-eclampsia or hyperten-
sion and who have undergone cervical ripening with oral 
misoprostol alone but require an additional augmenta-
tion agent after membrane rupture. Those women unable 
to give consent, with previous caesarean births, those 
who undergo cervical ripening with agents other than 
misoprostol (e.g. Foley catheter, other prostaglandins), 
with multiple pregnancy, a history of allergy to misopros-
tol or adequate uterine activity will be ineligible.
infusion. There is a need, therefore, to assess whether augmentation using oral misoprostol is superior clinically and 
economically to the standard protocol of intravenous oxytocin.
Trial registration: Clinical Trials.gov, NCT03 749902, registered on  21st Nov 2018.
Keywords: Pre-eclampsia, Induction of labour, Misoprostol, Oxytocin, Augmentation of labour, Randomized 
controlled trial, Study protocol
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After a decision has been made to induce labour, 
a patient information leaflet about the study will be 
given to the participant to read, consider and dis-
cuss with her partner and/or family. This leaflet will 
be available in local languages. Trained research staff 
will be available to answer any questions that women 
and their families have about the study. All will be 
assured that their participation is voluntary and that 
their decision to participate or not participate will not 
affect their clinical care. If the woman decides that 
she would like to participate in the study, research 
staff will ask the participant to sign a consent form, 
prior to any induction agent being administered. Par-
ticipants will be assigned a participant ID number and 
all study data will be maintained separate from any 
relevant identifiers to participant names. She would 
then commence cervical ripening with oral mis-
oprostol, as per routine practice. Following cervical 
ripening, the amniotic membranes will be ruptured 
artificially. If further uterine stimulation is required 
30 min after artificial rupture of membranes, and the 
patient wishes to continue participating in the study, 
she would be randomised into either the misoprostol 
or oxytocin group.
Randomization and masking
After the patient orally confirms her wish to participate 
in the trial, the research staff will open a sequentially 
numbered, sealed, opaque envelope containing the par-
ticipant’s group. Gynuity Health Projects will generate 
the envelopes using a randomisation code based on a 
computerised pseudo-random number generator. Ran-
domisation will be stratified by centre, with randomly 
determined block sizes of 4, 6 or 8. Neither the partici-
pating providers nor the participants will be blinded to 
the group assignment due to the complexity of titrating 
two separate uterotonics simultaneously.
Procedures
The study flow is shown in Fig. 1. All women who con-
sent to participate in the trial will undergo cervical ripen-
ing by the hospital staff who have received training in the 
study protocol. If the cervix is unfavourable, participants 
will receive oral misoprostol tablets (25 mcg) every 2  h 
for a maximum of 12 doses for cervical preparation. Once 
strong painful contractions (at least 3 in 10  min) have 
started, vaginal examination will be conducted. Contrac-
tion frequency will be assessed every 30 min and a vagi-
nal examination done every 4 h to assess cervical dilation 
Fig. 1 Randomized Trial Flowchart
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and Bishop score. Assessments may be conducted earlier 
if clinically indicated. The next dose of oral misopros-
tol will be omitted when moderate or strong contrac-
tions are occurring with a frequency of 3 in 10 min (i.e. 
9 or more in the preceding 30  min). If the contractions 
become inadequate again, and the cervix is not yet 2 cm 
dilated then the misoprostol can be restarted at 25mcg 
every 2 h. If a clinical decision is made to use a mechani-
cal method in addition to oral misoprostol for cervical 
preparation then the woman will no longer be eligible for 
the randomised trial. ’Artificial rupture of membranes’ 
(ARM) will be performed when the cervix is favourable 
(usually at 2 cm). No more cervical preparation doses of 
misoprostol will then be given. If spontaneous rupture of 
membranes occurs, then the cervical preparation doses 
of misoprostol will be stopped. If contractions are inad-
equate then further stimulation may be given as part of 
the randomised trial.
After membrane rupture, if contractions are continuing 
at 3 in 10 min (i.e., 9 or more in the preceding 30 min) 
or more and with progressive cervical change of at least 
1 cm every 2 h then labour will continue without further 
augmentation. These participants will not be randomised 
unless the frequency of contractions reduce, or if cervical 
change becomes inadequate (< 1 cm every 2 h). However, 
if contractions reduce to less than 3 in 10 min (under 9 in 
30 min) more than 30 min after ARM, then the next ran-
domisation envelope will be opened by a research assis-
tant, and the woman allocated to receive either continued 
oral misoprostol or an oxytocin infusion. The woman will 
also be eligible for randomisation if there is no progres-
sive cervical change over this time, even if contracting 
well. If there is hyperstimulation (more than 5 contrac-
tions in 10  min), then any ongoing stimulation with 
misoprostol or oxytocin will be stopped until the hyper-
stimulation resolves.
Women randomised to receive misoprostol will receive 
an initial dose of oral misoprostol 25mcg. The next dose 
of oral misoprostol will be omitted if moderate or strong 
contractions are occurring at 3 in 10  min or more (i.e., 
9 or more in the preceding 30 min). If contractions sub-
sequently reduce to less than 3 in 10 min (i.e., less than 
9 in 30 min) or become irregular or mild, then a further 
dose of oral misoprostol 25mcg will be administered, 
so long as 2 h have passed since the last dose. Oral mis-
oprostol 25mcg may be continued every two hours in the 
event of inadequate uterine activity. In the event of inad-
equate progress, clinicians will be advised to give addi-
tional misoprostol unless the contractions are very strong 
and frequent. If there is suspicion of fetal distress due to 
excessive uterine activity then no additional misoprostol 
will be administered and terbutaline 250 µg will be given 
subcutaneously.
Women randomised to oxytocin will receive an oxy-
tocin infusion through an intravenous cannula with 
an electronic infusion set. Five units of oxytocin will 
be injected in 500  mL of Ringer’s lactate, started at a 
rate of 2 mU/min, and increased every 30 min by 2 mU/
min until there are three to four contractions every 
10 min. The rate will be titrated to maintain that con-
traction frequency, with a maximum dose of 20  mU/
min. If contractions exceed five contractions in 10 min 
then the oxytocin infusion will stopped and the infu-
sion restarted at half the rate. If there is suspicion of 
fetal distress due to excessive uterine activity then the 
oxytocin infusion will be stopped. Terbutaline 250  µg 
subcutaneously will be given if excessive uterine activ-
ity persists.
For women in both groups, research staff will assess 
temperature and pulse every 2 h and the treating provider 
will perform a vaginal examination every 4  h to assess 
cervical dilation and progress. Research staff will docu-
ment contraction strength and frequency every 30  min 
and with any change in the infusion rate. Initial fetal 
monitoring will be with a Fetal Pinnard’s stethoscope or 
fetal Doppler auscultation every 30  min as per hospital 
policy. Continuous electronic fetal monitoring will be 
commenced in the event of abnormalities detected on 
intermittent auscultation, but discontinued again if the 
fetal heart rate tracing is normal. Research staff will doc-
ument the indication for and use of the cardiotocograph. 
Magnesium sulphate, steroids and anti-hypertensives will 
be given as per hospital protocols at provider discretion.
Research staff will ask all those recruited (whether 
eventually randomised or not) to complete an adapted 
version of the Mother-Generated Index (MGI) survey, 
the Mother Generated Birth Satisfaction Index (MGBSI) 
during the study [10, 11]. Research staff will administer 
a questionnaire at the time of recruitment to record the 
woman’s priorities and expectations for the induction 
process and labour. The research staff will administer a 
second questionnaire 24  h after the birth to assess the 
woman’s satisfaction with her pre-determined priorities, 
plus any other important issues. Together, the question-
naires will provide a quantitative satisfaction score as well 
as qualitative insights into the scoring. Research staff will 
also conduct a post-study interview with the woman 24 h 
after delivery and prior to discharge from the study hos-
pital in order to document future preferences for induc-
tion of labour methods and overall acceptability of labour 
induction method.
During their time in the study, research assistants will 
enter participant’s non-identifiable study data directly 
into a password protected electronic case report form 
(REDCap, Vanderbilt University, Tennessee). Data on 
pregnancy and neonatal outcomes will also be collected 
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from the hospital maternity records. The data will be 
stored on the handheld device until the device is syn-
chronised through an encrypted link with the host server. 
Data will be stored on a password-protected secure 
server located in India. Only researchers from the study 
will have access to the data.
Outcomes
The primary outcome will be caesarean birth, a core out-
come used in the Cochrane Collaboration induction of 
labour generic protocol [12], as the induction of labour 
core outcome set [13] had not been published at the 
time of protocol development. A tble of assessments is 
shown in Table 1. The need for caesarean birth combines 
the efficacy of the induction (important when induction 
is being conducted for hypertension in pregnancy) with 
the safety of the induction process for mother and fetus. 
It is a particularly important outcome as caesarean birth 
poses a serious risk to maternal health in the context of 
the setting and hypertensive disease. Secondary out-
comes will include measures of efficacy of the induction 
process (randomisation to birth interval; vaginal births 
within 12 and 24 h of randomisation; duration of hospital 
stay); additional outcomes to allow meta-analysis (start of 
induction to birth interval; cervix unchanged at 12 and 
24 h after the start of cervical preparation; vaginal births 
within 12 and 24 h after the start of cervical preparation); 
maternal complications (uterine tachysystole (defined 
as > 5 contractions in 10  min), uterine hypertonus 
(defined as a single contraction lasting over 2 min); and 
hyperstimulation syndrome (tachysystole/hypertonus 
with associated fetal heart rate abnormalities); uterine 
rupture; instrumental vaginal delivery; severe hyperten-
sion and HELLP Syndrome; maternal vomiting, diar-
rhoea or fever; antibiotic use; postpartum haemorrhage 
(> 1,000  ml, or any bleeding leading to systolic blood 
pressure less than 90 mmHg or diastolic blood pressure 
less than 60  mmHg or blood transfusion)) and serious 
maternal complications (intensive care unit admission; 
septicaemia; pulmonary oedema; cerebral haemorrhage 
or oedema; renal failure; eclampsia and maternal death). 
Maternal satisfaction will be assessed using a ‘Mother 
Generated Birth Satisfaction Index.’ Health economic 
data will also be collected to allow a full economic analy-
sis of the intervention.
Fetal or neonatal outcomes include neonatal morbidity 
(meconium-stained liquor; meconium-aspiration syn-
drome; fetal heart rate abnormality; Apgar score less than 
seven at five minutes; neonatal intensive care unit admis-
sion; seizures; neonatal encephalopathy (as assessed by 
the Sarnat score)); stillbirth; and perinatal death.
Sample size calculation
The sample size was estimated based on the primary out-
come of caesarean birth assuming a rate of 31% caesar-
ean birth for those receiving oxytocin for augmentation 
Table 1 Schedule of enrolment, interventions and assessments
STUDY PERIOD
Procedures Enrolment Allocation Post-allocation
24 h after birth Data taken from case 
notes after discharge
ENROLLMENT
Assessment of eligibility criteria X X
Signed consent form X
Randomisation X
INTERVENTIONS
Administration of study intervention (misoprostol 




Maternal complications X X X
Fetal / neonatal complications X X X
Serious maternal complications X X X
Cost effectiveness X
Efficacy of induction process X
Assessment of adverse events X X
Mother Generated Index X X
Participant Satisfaction Questionnaire X
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following cervical preparation with oral misoprostol. This 
is based on published data from a prior trial conducted 
in this population [14]. A total sample size of 520 women 
will provide (a) 90% power to detect a reduction in the 
caesarean rate from 31% to 18.5% (Relative Risk (RR) 
0.6), or (b) 80% power to detect a reduction in the caesar-
ean rate from 31 to 20% (RR 0.65) in those women who 
receive misoprostol (two sided α = 0.05). We estimate 
that we will need to approach and gain consent from 
1,000 women requiring induction of labour for hyper-
tension in order to find 520 who require augmentation 
after cervical preparation. When augmentation is indi-
cated, consented women will be randomised either to a 
protocol of continued oral misoprostol (n = 260) or to the 
standard oxytocin infusion (n = 260).
Statistical analysis
The trial statistician will provide the Independent Data 
and Safety Monitoring Committee (IDSMC) with a 
blinded report every 6 months via email for safety moni-
toring and will conduct one planned formal interim anal-
ysis after 200 women have been recruited. The interim 
analysis will be for safety and for effectiveness but not 
for futility; stopping rules will be in accordance with 
O’Brien-Fleming rules [14] whereby the effective alpha 
level will be 0.0054 (z = 2.782) for the interim analysis 
and 0.0492 (z = 1.967) for the final analysis. The IDSMC 
will have the authority to request further interim analyses 
if indicated; in the unlikely event this should this occur, 
revised stopping rules based on the O’Brien-Fleming 
principles will be calculated according to whether the 
additional analyses are requested before or after the for-
mal interim analysis at 12 months.
Safety reporting of Serious Adverse Reactions will 
occur from the period of randomisation until 48 h or dis-
charge, whichever is sooner. Reporting procedures will 
comply with regulatory authorities in the United King-
dom and India. Trial monitoring will be performed by 
staff at Gynuity Health Projects on behalf of the sponsor 
in accordance with the MOLI trial monitoring plan. The 
research team will share important protocol modifica-
tions with relevant parties including investigators, IRBs, 
trial registries and trial participants as appropriate and in 
compliance with relevant laws and regulations.
The primary analysis will be performed according to 
the intention-to-treat principle. The primary outcome 
measure will be evaluated using binomial regression 
models, initially unadjusted and then after adjustment for 
important potential confounding variables and covari-
ates. Binomial regression will be used for binary cat-
egorical measures, while ordinal regression will be used 
for multi-category variables. Count variables will use 
Poisson regression models and time measures using Cox 
proportional hazards regression models. All findings will 
be reported in accordance with the CONSORT guide-
lines for randomized trials.
All regression models will be run unadjusted (i.e., with 
treatment group as the only independent/ predictor 
variable) and then re-run with adjustment for important 
potential confounder variables/ covariates. These include 
(but are not necessarily confined to) mother’s age, ges-
tational age, cm dilatation before randomisation, receipt 
of magnesium sulphate in last 12 h, current anti-hyper-
tensive use, time from hospital admission to randomi-
sation of < 24  h, diastolic blood pressure at enrolment, 
proteinuria at enrolment, parity, and booked pregnancy. 
Other potential covariates will include variables found to 
differ by a clinically significant amount at baseline (post-
randomisation) and measures identified as potentially 
affecting outcome during the study period. Subgroup 
analysis will be by site of delivery, parity and gestational 
age. Within the constraints of the O’Brien-Fleming stop-
ping rules, overall statistical significance (across the 
interim and final analyses) will be set at the conventional 
5% level for primary outcomes and p < 0.01 for secondary 
outcomes. A statistical analysis plan will be completed 
prior to prior to the first comparative monitoring report 
to be presented to the IDSMC.
The ISDMC will oversee the safety of participants in 
the trial. The terms of reference of the ISDMC will be 
developed separately, based on the principles developed 
by the DAMOCLES group. The ISDMC, who will have 
full access to the trial results analysed by allocation, will 
report directly to the TSC with recommendations about 
the conduct of the trial as well as whether to continue or 
stop the trial. The ISDMC will have the following inde-
pendent voting members: Professor Diana Elbourne 
(London School of Hygiene and Tropical Medicine), 
Professor Asmita Muthal-Rathore (Maulana Azad Medi-
cal College and Loknayak Hospital, New Delhi), Dr Josh 
Vogel (Burnet Institute, Melbourne), and Dr Chris Sut-
ton, (The University of Manchester).
Discussion
Labour induction is one of the most commonly per-
formed obstetric procedures and increasingly com-
mon worldwide. In India, almost 1 in 6 deliveries are 
induced [15]. However, evidence documenting women’s 
experience and perceptions of the labour induction 
process and specific cervical ripening and augmenta-
tion agents is limited. Most qualitative studies of wom-
en’s experience have been conducted in North America 
and Europe [16, 17]. To help address this gap, our study 
has employed multiple methodologies – including the 
utilisation of a mother-generated birth satisfaction 
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index – to improve the recording and understanding 
of Indian women’s birth priorities and experiences. The 
use of misoprostol, an oral method for augmentation, 
has the potential to improve the patient experience by 
improving women’s mobility during labour. Together 
with the data from the mother-generated birth sat-
isfaction index, a planned sub-study will undertake 
semi-structured interviews before the start of the 
induction and after delivery with a sub-set of women, 
in order to understand the priorities, experiences and 
acceptability of induction of labour for women and 
explore any differences between the two randomized 
study groups.
We have also planned three additional analyses to 
help understand the implications of the research find-
ings for the broader health care system. First, as part 
of the planned qualitative study, our research team will 
conduct focus group discussions with health care work-
ers at the recruitment sites both before and 4–6 months 
into the randomised trial. We aim to improve under-
standing of the feasibility, usability and acceptability 
of the different induction regimes to health care pro-
fessionals and to explore potential barriers and solu-
tions for implementing research findings into clinical 
practice.
Second, we have also planned an economic evalu-
ation to assess patterns and levels of resource utilisa-
tion associated with each patient included in the two 
arms of the randomised trial of induction techniques. 
The analysis will help identify any variations in resource 
use (and overall health care expenditure) between the 
two treatment groups. Finally, we will also undertake 
a survey of health workers practicing in public health 
facilities in the two districts where the recruiting hos-
pitals are located to enhance our understanding of 
provider knowledge, attitudes and practices related to 
intrapartum uterotonic use. Together these additional 
analyses will help to contextualise the findings from 
this randomised trial, improving our understanding of 
how they can be best implemented and disseminated 
to improve Indian women’s birth experience during 
induction of labour.
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